ACROMEGALY AND COMORBIDITY: DIAGNOSIS AND TREATMENT
- Authors: Antsiferov M.B1, Astafyeva L.I2
-
Affiliations:
- Endocrinological Dispensary of the Moscow Healthcare Department
- SRI of Neurosurgery n.a. Acad. N.N. Burdenko
- Issue: No 4 (2018)
- Pages: 23-27
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295230
- ID: 295230
Cite item
Open Access
Access granted
Abstract
Acromegaly is a severe chronic neuroendocrine disease, accompanied by such concomitant conditions as diabetes mellitus, cardiovascular, respiratory, and musculoskeletal disorders, and an increase in the number of neoplasms. Development of these conditions is associated with an increase in the growth hormone and insulin-like growth factor 1 levels. Therefore, the pathogenetic treatment of acromegaly, namely the use of somatostatin analogues, remains the main method of treatment and prevention of concomitant diseases. Nevertheless, in a number of cases, additional symptomatic treatment is necessary in persisting symptoms and controlled course of the disease.
Keywords
Full Text
About the authors
M. B Antsiferov
Endocrinological Dispensary of the Moscow Healthcare DepartmentMoscow, Russia
L. I Astafyeva
SRI of Neurosurgery n.a. Acad. N.N. BurdenkoMD, Doctor at the Neurological Department Moscow, Russia
References
- Katznelson L. ,Laws E.R.Jr, Melmed S., Molitch M.E., Murad M.H., Utz A., Wass J.A. Acromegaly: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab 2014;99(11):3933-
- Lesen E. Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur. J. Endocrinol. 2017;176(2):203-12.
- Maione L., Brue T., Beckers A., et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur. J. Endocrinol. 2017;176(5):645-55.
- Анализ данных регистра пациентов с опухолями гипоталамо-гипофизарной области (ОГГО). Аналитический отчет 2016. Aston group.
- Дедов И.И., Мельниченко Г.А. и др. Клинические рекомендации. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. М., 2014.
- Trends in Endocrinology & Metabolism. 2016;27:470-83. Doi: (10.1016/j. tem.2016.04.014).
- Ramos-Levl A.M., Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine. 2017;55(2):346-59. doi: 10.1007/s12020-016-1191-3 2016.
- Katznelson L., Atkinson J., Cook D., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocrine Practice. 2011;17(Suppl. 4).
- Abreu A., Tovar A.P., Castellanos R., et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19:448-57.
- Annamalai A.K., Webb A., Kandasamy N., et al. A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy. J. Clin. Endocrinol. Metab. 2013;98(3):1040-50.
- Vitale G. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin. Endocrinol. 2005;63:470-76.
- Verdecchia P., Reboldi G., Angeli F., et al. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension. 2015;65(1):108-14. Doi: 10.1161/ HYPERTENSIONAHA.114.04310.
- Maffei P. Effects of 6 Months Treatment with Lanreotide Autogel on Metabolism and Blood Pressure in Acromegaly 2008, San Francisco; United States; ENDO 2008, The Endocrine Society's 90th Annual Meeting, ENDO 2008. San Francisco, California June 15-18, 2008.
- Caron P.J. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYSstudy. Clin. Endocrinol. 2016. doi: 10.1111/cen.13285.
- Baroni M.G., Giorgino F., Pezzino V., et al. Italian society of the study of diabetes/ Italian Endocrinological Society guidelines on the treatment of hyperglycemia on Cushing's syndrome and acromegaly. J. Endocrinol. Invest. 2016;39(2):235-55.
- Mazziotti G., Biagioli E., Maffezzoni F., et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 2015;100(2):384-94.
- Ben-Shlomo A. Clinical, quality of life, and economic value of acromegaly disease Control. Pituitary. 2011;14:284-94.
- Colao A. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin. Endocrinol. 2009;71:237-45.
- Lombardi G., Minuto F., Tamburrano G., et al. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with Acromegaly J. Endocrinol. Invest. 2009;32:202-9.
- Colao A., Pivonello R., Galderisi M., et al. Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy. J. Clin. Endocrinol. Metab. 2008;93(7):2639-46.
- Burton T., Le Nestour E., Bancroft T., Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary. 2013; 16:354-62.
- Иловайская И.А. Акромегалия: как на поликлиническом приеме узнать редкое заболевание? Поликлиника. 2015;3.
Supplementary files
